Patrick Daniel Donovan is a notable inventor based in Zionsville, IN (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-IL-17 antibody formulations. With a total of 3 patents to his name, Donovan's work has the potential to impact the treatment of various autoimmune diseases.

Latest Patents

Donovan's latest patents include innovative formulations for anti-IL-17 antibodies. One of his key inventions provides pharmaceutical formulations that can be used to treat conditions such as rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, and multiple myeloma. Another patent focuses on stabilized pharmaceutical formulations for these antibodies, which include components like citrate, sodium chloride, and polysorbate-80 at a pH of 5.7. These advancements aim to enhance the efficacy and stability of treatments for serious health conditions.

Career Highlights

Patrick Daniel Donovan is currently associated with Eli Lilly and Company, a leading pharmaceutical firm. His work at Eli Lilly has allowed him to collaborate with other talented professionals in the field, contributing to groundbreaking research and development.

Collaborations

Some of Donovan's notable coworkers include Vincent John Corvari and Barbara Ann Williams. Their collective expertise has fostered an environment of innovation and progress within the company.

Conclusion

Patrick Daniel Donovan's contributions to the field of pharmaceuticals through his patents on anti-IL-17 antibody formulations demonstrate his commitment to advancing medical treatments. His work not only showcases his inventive spirit but also highlights the importance of collaboration in achieving significant breakthroughs in healthcare.

This text is generated by artificial intelligence and may not be accurate.